Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

Increased Cell and Matrix Accumulation During Atherogenesis in Mice With Vessel Wall–Specific Deletion of Discoidin Domain Receptor 1

(2010) Christopher Franco et al.   CIRCULATION RESEARCH

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a ‘head-to-head comparison’

(2010) Gianantonio Rosti et al.   LEUKEMIA & LYMPHOMA

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

(2009) Paul W. Manley et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

(2009) G. Rosti et al.   BLOOD

Discoidin Domain Receptor 1 on Bone Marrow–Derived Cells Promotes Macrophage Accumulation During Atherogenesis

(2009) Christopher Franco et al.   CIRCULATION RESEARCH

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

(2009) Timothy Hughes et al.   JOURNAL OF CLINICAL ONCOLOGY

New Directions in the Treatment of Imatinib Failure and/or Resistance

(2009) Francis J. Giles   SEMINARS IN HEMATOLOGY

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

(2008) S. Branford et al.   BLOOD

Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease

(2008) Peter Valent   BRITISH JOURNAL OF HAEMATOLOGY

Discoidin Domain Receptor 1 ( Ddr1 ) Deletion Decreases Atherosclerosis by Accelerating Matrix Accumulation and Reducing Inflammation in Low-Density Lipoprotein Receptor–Deficient Mice

(2008) Christopher Franco et al.   CIRCULATION RESEARCH

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

(2008) Elizabeth Day et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases

(2008) Alfonso Quintás-Cardama et al.   Future Oncology

New therapeutic approaches and prognostic factors in chronic myeloid leukemia

(2008) Giuseppe Saglio et al.   LEUKEMIA & LYMPHOMA